T-cell adoptive therapy of tumors: Mechanisms of improved therapeutic performance

Critical Reviews in Immunology

Volumn 21, Issue 1-3, 2001, Pages 215-248

  Peng, Liaomin ^a   Cohen, Peter A ^a   Kjaergaard, Jorgen ^a   Plautz, Gregory E ^a   Finke, James H ^a   Koski, Gary K ^b   Czerniecki, Brian J ^c   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CD4+ T cells; CD8; Cytotoxic T cells; Dendritic cells; Helper independent T cells; Interferon ; L selectin(low) T cells; Lymphokine activated killer cells; T cells; Tumor rejection; Tumoricidal macrophages

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; L SELECTIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; APOPTOSIS; CELL COMMUNICATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONFERENCE PAPER; DENDRITIC CELL; EFFECTOR CELL; HELPER CELL; HUMAN; MELANOMA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CELL COMMUNICATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS; LYMPHOCYTE ACTIVATION; MODELS, ANIMAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 0034798589     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (283)

1. Spontaneous regression of malignant melanoma. Pathologic and immunologic study in a ten year survivor
2. Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells
3. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report
4. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2
5. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators
6. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
7. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors
8. +/CD62L low T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression
9. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
10. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
11. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy
12. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
13. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2
14. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization
15. T-cell mediated rejection of established tumors displays a varied requirement for perforin and IFN-gamma expression which is not predicted by in vitro lytic capacity
16. + tumor-infiltrating lymphocytes
17. + cytotoxic T-cells
18. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
19. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
20. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
21. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
22. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based immunotherapies?
23. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
24. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes
25. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter
26. + T lymphocytes
27. MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells
28. A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation
29. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes
30. T-cell-receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis
31. Graft tolerance: A duel of two signals
32. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo
33. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
34. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function
35. Freshly isolated spleen dendritic cells and epidermal Langerhans cells undergo similar phenotypic and functional changes during short-term culture
36. Antigen processing and presentation by epidermal Langerhans cells, induction of immunity or unresponsiveness
37. The challenge of preparing human dendritic dells for tumor vaccine therapies
38. Calcium ionophore treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells
39. Stimulation of Langerhans cell migration by tumor necrosis factor alpha (TNF-alpha)
40. Dendritic cells: Migratory cells that are attractive
41. Cytokines and their effects on maturation, differentiation and migration of dendritic cells
42. Maturation and migration of cutaneous dendritic cells
43. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status or sensitivity to biologic agents
44. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells
45. Dendritic cells in the T-cell areas of lymphoid organs
46. Dendritic cells require maturation via CD40 to generate protective antitumor immunity
47. + T-helper and a T-killer cell
48. Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways
49. + monocytes through distinct pathways that converge on NF-κB
50. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile
51. + T cells in tumor rejection: Past evidence and current prospects
52. Propagation of murine and human T cells with defined antigen specificity and function
53. + T cells in culture with maintained antigen specificity
54. + monocyte derived dendritic cells and the implications for cancer vaccines
55. Cross presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors
56. Recognition and destruction of target cells by tumoricidal macrophages
57. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes
58. Neoplastic cells that express low levels of MHC class I determinants escape host immunity
59. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L)
60. Tumor immunity in perforin-deficient mice: A role for CD95 (Fas/APO-1)
61. The Fas-based mechanism of lymphocytotoxicity
62. The CTL's kiss of death
63. The Fas death factor
64. Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules
65. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes
66. Local T helper cell signals by lymphocytes infiltrating intraocular tumors
67. + anti-tumor T cells requires tumor expression of cell surface MHC class II molecules
68. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors
69. Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells
70. Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: Tumor size influences the response to therapy
71. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics
72. Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2 expression
73. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon-alpha in interleukin-6 (IL-6)- dependent and IL-6-independent multiple myeloma cell lines
74. Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: Enhancement of effect by batimastat
75. Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line
76. An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells
77. Transcriptional control of the human plasma membrane phospholipid scramblase 1 gene is mediated by interferon-alpha
78. Exposure of phosphatidylserine is a general feature in the phagocytosis of apoptotic lymphocytes by macrophages
79. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes
80. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: Survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy
81. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells
82. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues
83. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes
84. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes
85. Efficient activation of human blood monocytes to a rumoricidal state by liposomes containing human recombinant gamma interferon
86. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells
87. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction
88. Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors
89. Polymorphonuclear leukocyte-induced detachment of cultured epidermal carcinoma cells from the substratum
90. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid
91. Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants
92. Differential regulation of interleukin-12- and interleukin-15-induced natural killer cell activation by interleukin-4
93. Murine lymphokine-activated killer (LAK) cells: Phenotypic characterization of the precursor and effector cells
94. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis
95. Macrophages and metastasis - A biological approach to cancer therapy
96. The putative role of arylsulfatase in interleukin-2-mediated cytotoxicity and interleukin-7-mediated bactericidal activity of natural killer cells
97. Prostaglandins from human T suppressor/cytotoxic cells modulate natural killer antibacterial activity
98. Antibacterial activity of human natural killer cells
99. Selective phagocytosis of gram-positive bacteria and interleukin 1-like factor production by a subpopulation of large granular lymphocytes
100. Cytolytic and biochemical properties of cytoplasmic granules of murine lymphokine-activated killer cells
101. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages
102. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors
103. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii
104. Assessment of human natural killer and lymphokine-acrivated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts
105. Lymphokine-activated killer cells lyse Listeria-infected hepatocytes and produce elevated quantities of interferon-gamma
106. Stimulatory receptors in NK and T cells
107. Function and specificity of human natural killer cell receptors
108. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes
109. NK-cell receptors and recognition of MHC class I molecules
110. Tumor cell surfaces: General alterations detected by agglutinins
111. Phytohemagglutinin-L (PHA-L) lectin surface binding of N-linked beta 1-6 carbohydrate and its relationship to activated mutant ras in human pancreatic cancer cell lines
112. Tumor cell surface beta 1-4-linked galactose binds to lectin(s) on microvascular endothelial cells and contributes to organ colonization
113. Endogenous lectins as mediators of tumor cell adhesion
114. Transformation-related changes in the expression of endogenous cell lectins
115. Inhibition of lectin-mediated ovarian tumor cell adhesion by sugar analogs
116. The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research
117. Lectin-binding properties of human breast cancer cell lines and human milk with particular reference to Helix pomatia agglutinin
118. Reactivity of mucin-specific lectin from Sambucus sieboldiana with simple sugars, normal mucins and tumor-associated mucins. Comparison with other lectins
119. Different patterns of lectin binding and cell surface sialylation detected on related high- and low-metastatic tumor lines
120. Neoglycoproteins with the synthetic complex biantennary nonasaccharide or its alpha 2,3/alpha 2,6-sialylated derivatives: Their preparation, assessment of their ligand properties for purified lectins, for tumor cells in vitro, and in tissue sections, and their biodistribution in tumor-bearing mice
121. Detection of tumor-associated expression of caxbohydrate-binding proteins (lectins). The use of neoglycoproteins and neoglycoenzymes in glycohistochemical and glycocytological studies
122. Interaction of immobilized recombinant mouse C-type macrophage lectin with glycopeptides and oligosaccharides
123. Binding of activated macrophages to tumor cells through a macrophage lectin and its role in macrophage tumoricidal activity
124. Lectin-like molecules on the murine macrophage cell surface
125. Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro
126. Mechanisms of macrophage-mediated tumor cytolysis
127. Characterization of the recognition of target cells sensitive or resistant to cytolysis by activated rat peritoneal macrophages
128. Characterization of the recognition of target cells sensitive to or resistant to cytolysis by activated macrophages. II. Competitive inhibition of macrophage-dependent tumor cell killing by mitogen-induced, nonmalignant lymphoblasts
129. Sensitivity to macrophage-mediated cytostasis is cell cycle dependent
130. Activated macrophages selectively bind both normal and neoplastic lymphoblasts but not quiescent lymphocytes
131. Susceptibility of malignant and normal target cells to the cytotoxic action of bone-marrow macrophages activated in vitro with the macrophage cytotoxicity factor (MCF)
132. Lysis of pulmonary fibroblasts by lymphokine (IL-2)-activated killer cells - A mechanism affecting the human lung microenvironment?
133. Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells
134. Ly-6C+ natural T (NT) cells mediate immune surveillance against NK-sensitive and NK-resistant transplantable tumours in certain strains of mice
135. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes
136. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice
137. Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells
138. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas-tumor cells
139. Fas ligand induction in human NK cells is regulated by redox through a calcineurin-nuclear factors of activated T cell-dependent pathway
140. Molecular mechanisms of immune-mediated lysis of murine renal cancer: Differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells
141. Induction of Fas ligand in murine bone marrow NK cells by bacterial polysaccharides
142. Effects of interferon-alpha and gamma on development of LAK activity from mononuclear cells in breast cancer patients
143. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: Implications for the innate immune response
144. Natural killer cell cytokine production, not cytotoxicity, contributes to resistance against blood-stage Plasmodium chabaudi AS infection
145. NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection
146. + NK and LAK cells
147. + NK and LAK cells
148. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells
149. Recognition and destruction of target cells by tumoricidal macrophages
150. All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity
151. A lymphokine-activated killer (LAK)-resistant cell line, and low expression of adhesion molecules LFA-3 and VCAM-1 on its cell surface
152. Macrophage binding of cells resistant and sensitive to contact-dependent cytotoxicity
153. Characterization of macrophage recognition and killing of SV40-transformed tumor cells that are "resistant" or "susceptible" to contact-mediated killing
154. Macrophage-resistant murine simian virus 40 tumors express a retroviral type-specific gp70
155. Comparative analysis of natural killer cell and macrophage recognition of concanavalin A-resistant Chinese hamster ovary cells: Role of membrane oligosaccharides
156. Alterations in sensitivity to nonspecific cell-mediated lysis associated with tumor progression: Characterization of activated macrophage- and natural killer cell-resistant tumor variants
157. Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity
158. Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated killer-cell-mediated lysis: Evidence for deficiency of binding and post-binding events
159. Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms
160. BCG cancer (first of two parts)
161. Abrogation of antitumor effects of Corynebacterium parvum and BCG by antimacrophage agents: Brief communication
162. BCG cancer
163. Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity
164. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer
165. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer
166. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy
167. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer
168. Evaluation of local immune response after intravesical bacille Calmette-Guerin treatment for superficial bladder cancer
169. Evaluation of cellular immunity following bacillus Calmette-Guerin therapy in patients with superficial bladder cancer
170. Role of the immune response in BCG for bladder cancer
171. Adjuvant BCG immunotherapy for malignant melanoma
172. Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes
173. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2-lymphocytes
174. + T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment
175. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells
176. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice
177. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy
178. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity
179. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2
180. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma
181. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
182. Role of T cell subsets in tumor immunity
183. Adoptive immunotherapy of a newly induced sarcoma: Immunologic characteristics of effector cells
184. Adoptive immunotherapy of newly induced murine sarcomas
185. Sequential development of structural and functional alterations in T cells from tumor-bearing mice
186. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice
187. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present
188. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules
189. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor
190. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes
191. Systemic T cell adoptive immunotherapy of malignant gliomas
192. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells
193. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells
194. Secretion of biologically active superantigens by mammalian cells
195. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2
196. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells
197. Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors
198. Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene
199. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4
200. Activation of T lymphocytes for the adoptive immunotherapy of cancer
201. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes
202. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells
203. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells
204. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents
205. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor
206. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases
207. A novel role for autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma
208. Enhancing effect of interleukin 1 alpha administration on antitumor effector T-cell development
209. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2
210. Treatment of subcutaneous tumor with adoptively transferred T cells
211. Purification of L-selectin-(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
212. Requirements for T cell recognition and elimination of retrovirally-transformed cells
213. + cytotoxic T lymphocytes express IL-1 receptors and require IL-1 for secretion of IL-2
214. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression
215. Rapid modulation of homing receptors (gp90MEL-14) induced by activators of protein kinase C. Receptor shedding due to accelerated proteolytic cleavage at the cell surface
216. Down-regulation of homing receptors after T cell activation
217. Reversibility of loss of homing receptor expression following activation
218. + effector T cells in vivo: Immunization results in a transient population of MEL-14-, CD45RB-helper cells that secretes interleukin 2 (IL-2), IL-3, IL-4, and interferon gamma
219. Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells
220. + T cell reactivity to a model tumor antigen
221. + T cell-dependent
222. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
223. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
224. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL
225. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
226. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory
227. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: Correlation with clonal IL 2 receptor expression
228. + T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness
229. + T cell- and IL-2-dependent mechanism
230. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
231. Costimulatory regulation of T cell function
232. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
233. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
234. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro
235. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells
236. Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases
237. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases
238. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
239. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes
240. Ganglioside composition of the rat choriocarcinoma cell line, Rcho-1
241. Glycosphingolipid composition of rat placenta: Changes associated with stage of pregnancy
242. Glycoprotein and ganglioside changes in human trophoblasts after exposure to pulsed Doppler ultrasound
243. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
244. Immunologic dysfunction in cancer
245. Changes in the expression of the type-2 but not the type-1 cyclo-oxygenase enzyme in chorion-decidua with the onset of labour
246. Prostaglandin E2 production by endogenous secretion of interleukin-1 in decidual cells from term fetal membrane
247. Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: Suppression by glucocorticoids and NSAIDs
248. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease
249. Expression of interleukin-10 in human gestational tissues
250. Cytokine-mediated PGE2 expression in human colonic fibroblasts
251. Possible involvement of interleukin-1 in cyclooxygenase-2 induction after spinal cord injury in rats
252. Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells
253. PGE2 and TXA2 production by isolated macrophages from human placenta
254. A T-helper-2 bias in decidua: The prostaglandin contribution of the macrophage and trophoblast
255. T-cell modulation in decidua
256. T cells of the human intestinal lamina propria are high producers of interleukin-10
257. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease
258. The effect of prostaglandin E1 on experimental colitis in the rat
259. Alteration of prostaglandin E2 and leukotriene B4 synthesis in chronic inflammatory bowel disease
260. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12
261. Cyclooxygenase-2 unlike cyclooxygenase-1 is highly expressed in bovine embryos during the implantation period
262. Coordinate expression of inducible nitric oxide synthase and cyclooxygenase-2 genes in uterine tissues of endotoxin-treated pregnant mice
263. Cyclooxygenase-1 and -2 in human placenta and placental bed after normal and pre-eclamptic pregnancies
264. Regulation of decidual cell and chorion cell production of interleukin-10 by purified bacterial products
265. Multiple female reproductive failures in cyclooxygenase 2-deficient mice
266. Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induces epithelial prostaglandin h synthase-2 expression and prostaglandin E2 and F2alpha production
267. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E
268. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance
269. Differential gene expression of TGF-beta isoforms and TGF-beta receptors during the first trimester of pregnancy at the human maternal-fetal interface
270. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)- deficient mice through an IL-12- and gamma interferon-dependent mechanism
271. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice
272. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2
273. Interleukin-10 reduces the systemic inflammatory response in a murine model of intestinal ischemia/reperfusion
274. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation
275. + T cells
276. Transforming growth factor-beta gene therapy ameliorates experimental colitis in rats
277. The immunology of pregnancy
278. The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces
279. Apoptosis of T cells in the first trimester human decidua
280. Death receptor Fas/Apo-1/CD95 expressed by human placental cytotrophoblasts does not mediate apoptosis
281. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2-T cells. Tumor eradication does not require participation of cytotoxic T cells
282. + T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens
283. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells